Rachel White, MD
Pediatrics · Jacksonville, ARNPI 1366481392
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,078 and has fallen 61.0% since, to $420 in 2025. Among pediatrics clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$843
- AbbVie$736
- AstraZeneca$444
- Novo Nordisk$434
- Pfizer$321
- Abbott$288
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $843 |
| AbbVie(2 entities) | 51 | $736 |
| AstraZeneca | 21 | $444 |
| Novo Nordisk | 26 | $434 |
| Pfizer | 24 | $321 |
| Abbott | 14 | $288 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $270 |
| Boehringer Ingelheim | 16 | $250 |
| Amgen | 9 | $142 |
| Lilly USA, LLC | 9 | $131 |
| Optinose US, Inc. | 1 | $131 |
| Exact Sciences | 6 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $98 |
| Sanofi Pasteur Inc. | 4 | $75 |
| Novartis | 5 | $73 |
| Merck | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Johnson & Johnson | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Gilead | 2 | $30 |
| Mylan Specialty L.p. | 1 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Lundbeck LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Scynexis, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,787 in reported general payments places this provider in the 95th percentile of 464 pediatrics providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $92,499 |
| JardianceEmpagliflozin | 78 | $82,961 |
| EliquisApixaban | 68 | $61,481 |
| EntrestoSacubitril/Valsartan | 32 | $53,239 |
| JanuviaSitagliptin Phosphate | 36 | $48,785 |
| OzempicSemaglutide | 38 | $46,591 |
| RybelsusSemaglutide | 23 | $32,859 |
| LinzessLinaclotide | 36 | $23,052 |
| FarxigaDapagliflozin Propanediol | 13 | $21,501 |
| MounjaroTirzepatide | 15 | $18,744 |
| TrulicityDulaglutide | 15 | $16,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $15,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,125 |
| Gabapentin | 222 | $5,358 |
| Omeprazole | 245 | $4,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $843 | $107,56594 claims |
| Boehringer IngelheimJardiance | $250 | $82,96178 claims |
| Novo NordiskOzempic, Rybelsus | $434 | $79,45061 claims |
| PfizerEliquis | $321 | $61,48168 claims |
| NovartisEntresto | $73 | $53,23932 claims |
| MerckJanuvia | $64 | $48,78536 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $444 | $35,62527 claims |
| Lilly USA, LLCMounjaro, Trulicity | $131 | $35,31530 claims |
| AbbVieLinzess | $736 | $23,05236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 464 pediatrics providers in Arkansas.
Other pediatrics in Jacksonville
- Howard OrsburnRussellville$71K
- David GoodmanWest Memphis$61K
- Robert PesekLittle Rock$20K
- Peyton MillsLittle Rock$7K
- Eduardo OchoaLittle Rock$4K
- Laura MarrattLittle Rock$4K
- Jane MiersSherwood$4K
- Jennifer JohnsonFort Smith$4K
- Ashley DavisSherwood$3K
- John SimmonsFayetteville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.